Download Reaching New Heights in the Management of Non

Reaching New Heights
in the Management of
Non-Small Cell Lung Cancer:
This activity is provided
by prIME Oncology.
Focus on EGFR-Targeted Therapy
Monday
5 December 2016
17.45 –19.15
Hall C7
Messe Wien Exhibition
& Congress Center
Messeplatz 1
Vienna, Austria
This program was approved by the IASLC 17th World Conference on Lung Cancer Program
Committee as an independent activity held in conjunction with the IASLC 17th World Conference
on Lung Cancer. This program is not sponsored or endorsed by IASLC.
This educational activity is supported by Boehringer Ingelheim Pharma GmbH & Co. KG.
Reaching New Heights
in the Management of
Non-Small Cell Lung Cancer:
Focus on EGFR-Targeted Therapy
Monday, 5 December 2016
17.45–19.15
Hall C7
Messe Wien Exhibition
& Congress Center
Chair
Martin Schuler, MD
German Cancer Center
University Hospital Essen
Essen, Germany
Faculty
Barbara Melosky, MD, FRCPC
British Columbia Cancer Agency
Vancouver, British Columbia, Canada
Marianne Nicolson, MD, FRCP
Aberdeen Royal Infirmary
Aberdeen, Scotland
Keunchil Park, MD, PhD
Samsung Medical Center
Sungkyunkwan University
Seoul, South Korea
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology.
This activity provides content that is evidencebased, balanced, and free of commercial bias, with
a primary objective to improve competence and
performance of learners in order to improve patient care.
Sunshine Act and EFPIA Disclosure Code
prIME Oncology complies with all Sunshine Act
reporting requirements as outlined by CMS and
applicable manufacturers and with EFPIA Disclosure
Code reporting requirements.
Agenda
17.45 Welcome and warm-up quiz
Martin Schuler, MD
17.50 Key decision points for personalized
patient care of advanced non-small cell
lung cancer (NSCLC)
Martin Schuler, MD
18.00 Managing EGFR–mutant
adenocarcinoma: What is the optimal
first-line approach?
Barbara Melosky, MD, FRCPC
18.20 Tackling acquired resistance to EGFR–
targeted therapy: Evaluating current and
emerging treatment strategies
Keunchil Park, MD, PhD
18.40 Contemporary management of
squamous cell carcinoma: What is the role
of EGFR–targeted therapy in the era
of immunotherapy?
Marianne Nicolson, MD, FRCP
18.55 Quiz questions revisited and questions
from the audience
Martin Schuler, MD, and Faculty Panel
19.10 prIME Points™
Martin Schuler, MD
19.15 Adjourn
Register online: www.prIMEoncology.org/egfr-vienna